# Cannabis Advocacy Groups Push Congress For Legalization And Other Reforms Following … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-advocacy-groups-push-congress-for-legalization-and-other-reforms-following/ > **Published:** 2026-05-20T10:28:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T14:00:25-04:00 > **Clinical Summary:** Clinical guide to cannabis use in older adults, drug interactions, and evidence gaps as legalization expands. --- ✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchAgingAnxietyMental HealthSafetyIndustry Clinical Summary Cannabis advocacy groups are mobilizing congressional efforts to advance federal legalization and related policy reforms, particularly in response to increasing marijuana use among older adults who are turning to cannabis as an alternative to conventional medications. This demographic shift reflects a growing population of patients seeking cannabis for conditions such as [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), insomnia, and anxiety, yet the current federal prohibition creates significant barriers to [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), standardized dosing, and physician guidance for this vulnerable age group. Policy changes at the federal level would enable more rigorous pharmacological and safety studies, particularly regarding drug interactions with the multiple medications older patients typically take, while also reducing legal and stigma-related barriers that prevent patients from disclosing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) to their healthcare providers. The coalition’s push for legalization highlights a disconnect between patient behavior and clinical evidence, as many older adults are self-treating without medical oversight due to lack of access to cannabis-knowledgeable physicians and concerns about legal repercussions. Clinicians should anticipate that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) among older patients will likely increase regardless of policy changes, making it essential to develop screening protocols and evidence-based guidance now. Physicians should proactively ask older patients about cannabis use and stay informed about emerging evidence to provide appropriate counseling on risks, benefits, and drug interactions relevant to their individual clinical situations. Dr. Caplan’s Take “What we’re seeing with older adults turning to cannabis is a rational response to inadequate pain management options, but we need to be honest that our evidence base for dosing and drug interactions in this population is still dangerously thin, and legalization without parallel investment in rigorous [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) will leave my patients vulnerable to harm.” Clinical Perspective As advocacy groups intensify efforts to reshape federal cannabis policy, clinicians should recognize that legalization momentum may accelerate patient access to cannabis, particularly among older adults seeking alternatives to conventional medications. The limited clinical evidence base for cannabis efficacy in aging populations stands in tension with growing consumer enthusiasm, making it important for providers to distinguish between advocacy claims and peer-reviewed data on safety and drug interactions in elderly patients taking multiple medications. Confounding factors like variable cannabinoid concentrations across products, heterogeneous patient populations, and the challenge of disentangling cannabis effects from placebo responses complicate clinical decision-making. Regardless of policy direction, clinicians should proactively develop competence in cannabis counseling, including risk stratification for dependence and cognitive effects in older adults, and establish clear protocols for documentation and monitoring in patients who choose to use cannabis therapeutically. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Advocacy%20Groups%20Push%20Congress%20For%20Legalization%20And%20Other%20Reforms%20Following%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55830)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55830)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Advocacy%20Groups%20Push%20Congress%20For%20Legalization%20And%20Other%20Reforms%20Following%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55830)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Police And Anti-Drug Groups Call On Key Congressional Leaders To Let Hemp THC Ban …](https://cedclinic.com/hemp-thc-regulation-challenges-farm-bill/) - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.marijuanamoment.net/cannabis-advocacy-groups-push-congress-for-legalization-and-other-reforms-following-trumps-rescheduling-move/](https://www.marijuanamoment.net/cannabis-advocacy-groups-push-congress-for-legalization-and-other-reforms-following-trumps-rescheduling-move/) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) CED Clinic Blog[Fear of recurrence, secondary cancers, and health problems in long-term survivors of childhood cancer: Findings from a Canadian cohort.](https://cedclinic.com/fear-of-recurrence-secondary-cancers-and-health-problems-in-long-term-survi/) CED Clinic Blog[Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days.](https://cedclinic.com/associations-of-cannabis-use-other-substances-and-lifestyle-choices-on-anxi/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).